- 15 Jan 2021 – Alligator Bioscience appoints Chief Scientific Officer
- 11 Jan 2021 – The subscription period in Alligator Bioscience’s rights issue commences today
- 30 Dec 2020 – Alligator Bioscience publishes prospectus in connection with forthcoming rights issue
- 29 Dec 2020 – Alligator Bioscience recruits new Chief Medical Officer
Preferential rights issue 2021
“With the capital injection from the rights issue, we secure the start of important efficacy studies for our focus projects mitazalimab and ATOR-1017. Just before year-end, we submitted a CTA for mitazalimab, an application to start Phase II in pancreatic cancer. For ATOR-1017, we plan to start Phase II studies in the second half of 2021, with gastric cancer as a prioritized indication. Based on strong data from preclinical models and clinical Phase I, we see great opportunities for both mitazalimab and ATOR-1017 to successfully treat patients with these cancers.”– Per Norlén, CEO
Listen more about the offer here (in Swedish).